top of page

Rachel Haurwitz on Caribou's #ASCO24 data and the rationale for taking time to look further at HLA matching for allo CAR-T

Rachel Haurwitz elaborates on the data update for CB-010 that was presented at ASCO and describes why the company will push back the start of a pivotal trial approximately six months to better understand how HLA matching potentially affects efficacy.


Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight


Breakthrough Properties is a life science real estate company that is exclusively focused on delivering cutting-edge environments for the life science industry. With a portfolio of roughly 5 million square feet across the US, UK and continental Europe, Breakthrough has emerged as a leading partner for high-growth biotechs and pharmas around the world. 

bottom of page